Treatment of pre- and postmenopausal Women with HR+/HER2-metastatic Breast Cancer Ribociclib receives high AGO Recommendation Level

被引：0
|
作者：
Rudesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [31] Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [32] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [33] Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
    Song, Yan
    Hao, Yanni
    Macalalad, Alexander R.
    Lin, Peggy L.
    Signorovitch, James E.
    Wu, Eric Q.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 67 - 72
  • [34] BUDGET IMPACT ANALYSIS OF FIRST-LINE RIBOCICLIB IN THE TREATMENT OF PRE- AND POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN THE UNITED STATES
    Zhou, J.
    Edwards, M. L.
    Fang, H.
    Oderda, G.
    Brixner, D.
    Biskupiak, J. E.
    Balu, S.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [35] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish A.
    Trivedi, Meghana V.
    PHARMACOECONOMICS, 2023, 41 (06) : 709 - 718
  • [36] Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [38] Initial ribociclib plus endocrine therapy for HR+/HER2-advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study
    Shao, Zhimin
    Tong, Zhongsheng
    Liu, Qiang
    Li, Wei
    Cai, Li
    Shen, Kunwei
    Li, Huiping
    Wang, Chuan
    Yang, Jin
    Song, Zhenchuan
    Wang, Shui
    Luo, Ting
    Zhao, Wenhe
    Wang, Haibo
    Pan, Yueyin
    Nie, Jianyun
    Zeng, Xiaohua
    Bai, Yanqing
    Chiang, Wendy
    Guarnaccia, Valeria
    Bi, Yu
    Xu, Binghe
    CANCER MEDICINE, 2024, 13 (15):
  • [39] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [40] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
12345